Collectively, CBM treatments may improve pain scores, but study limitations such as small sample sizes and study durations, high placebo response rates, and trial unblinding because of the psychoactive effects of cannabinoids all hinder data interpretation and the extrapolation to chronic pain conditions.
Regular cannabinoid use and inflammatory biomarkers: Systematic review and hierarchical meta-analysis.
A comprehensive systematic review of cannabis inflammatory biomarkers found associations with anti-inflammatory markers in observational studies. However, the clinical significance of these laboratory changes remains uncertain, and the predominance of observational data limits causal conclusions about cannabis as an anti-inflammatory intervention.
Health-related quality of life in patients receiving medicinal cannabis: systematic review and meta-analysis of primary research findings 2015-2025.
A comprehensive systematic review and meta-analysis examining medicinal cannabis quality of life outcomes found consistent improvements across chronic conditions. The research analyzed validated HRQL measures from 2015-2025, showing benefits in short, medium, and long-term follow-up periods across diverse patient populations.
Prevalence of schizophrenia spectrum and bipolar disorder among patients with cannabis induced psychosis: a systematic review and meta-analysis.
Distinguishing cannabis-induced psychosis from primary psychiatric disorders is difficult and has significant clinical and prognostic implications. Current t…
The association between major depressive disorder and cannabis use disorder: A meta-analysis and meta-regression analysis.
Major Depressive Disorder (MDD) and Cannabis Use Disorder (CUD) frequently co-occur, yet prevalence estimates vary widely across settings. This meta-analysis…
Efficacy and Safety of Cannabinoids for Neuropsychiatric Symptoms of Dementia: A Systematic Review with Meta-analysis.
Neuropsychiatric symptoms (NPS) are highly prevalent in persons with dementia and have been associated with adverse health outcomes. Neuropsychiatric symptom…
Effect of Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) on Neuropsychiatric Outcomes: A Systematic Review and Meta-Analysis.
A comprehensive meta-analysis of 82 studies reveals GLP-1 receptor agonists neuropsychiatric effects may include Parkinson’s disease risk reduction. However, evidence quality remains low, limiting clinical recommendations beyond established metabolic indications.
Endocannabinoid System Cannabis Pregnancy Autism ADHD Risk
Clinical Takeaway Clinical Takeaway: A meta-analysis of 13 observational studies found that maternal cannabis use during pregnancy was associated with a 30% increased risk of autism spectrum disorder and a 13% increased...
Analgesic Effect of Cannabinoids for Fibromyalgia: A Systematic Review and Meta-Analysis.
Fibromyalgia is a kind of complex chronic pain syndrome that exerts a profound impact on patients’ lives. Current pharmacological treatments for fibromyalgia…
Efficacy and Safety of Cannabinoids for Neuropsychiatric Symptoms of Dementia: A Systematic Review with Meta-analysis.
Neuropsychiatric symptoms (NPS) are highly prevalent in persons with dementia and have been associated with adverse health outcomes. Neuropsychiatric symptom…